Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

類似資料

• Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
  著者:: Fischer, Thomas, 等
  出版事項: (2010)
• Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
  著者:: del Corral, Adam, 等
  出版事項: (2012)
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
  著者:: Stone, Richard M., 等
  出版事項: (2017)
• How I treat newly diagnosed chronic phase CML
  著者:: Cortes, Jorge, 等
  出版事項: (2012)
• FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia: The Start of an Era?
  著者:: Pemmaraju, Naveen, 等
  出版事項: (2011)